CC-42344 - Influenza A PB2 Inhibitor

Program Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3
Pandemic Influenza A CC-42344 PB2 Inhibitor
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase complete
Phase 2b Phase complete
Phase 3 Phase complete

CC-42344, our lead molecule, binds to a highly conserved PB2 site of influenza polymerase complex and exhibits a novel mechanism of action which inhibits replication. CC-42344 has shown excellent antiviral activity against influenza A strains, including avian pandemic strains and Tamiflu® resistant strains, and shows favorable pharmacokinetic and drug resistance profiles. CC-42344 is currently being evaluated in preclinical IND-enabling studies for the treatment of influenza.